Mara Antonoff, Associate Professor of Thoracic and Cardiovascular Surgery at MD Anderson Cancer Center, shared a post by DAVA Oncology on X, adding:
“Honored to present surgical insights from NORTHSTAR at DAVA Oncology Summit
- NORTHSTAR was NOT another OMD trial
- Most patients had polymetastatic EGFR-mutant NSCLC, yet LCT improved PFS
- Surgery provided critical insights into treatment response, residual disease, and tumor biology.”
Quoting DAVA Oncology‘s post:
“NORTHSTAR surgical update: Mara Antonoff, MD Anderson Cancer Center reports lung resection after Osi in EGFR-mutant stage IV NSCLC was safe, median LOS 3 days, 9.5% pCR and PFS endpoint met.
Study explores:
- Which patients benefit?
- When should we operate?
- What can surgery teach us?”
Other articles about NORTHSTAR on OncoDaily.
